Lactate emerges as a metabolic driver of maladaptive kidney repair

A new mechanistic study in kidney injury connects a familiar metabolic byproduct to an unfamiliar epigenetic-like switch inside tubular cells. Lactate, long treated as a marker of hypoxia and altered metabolism, now appears to participate directly in the transition from acute kidney injury to chronic fibrotic disease through DDX18 lactylation and downstream stabilization of CD44 mRNA.

The clinical premise is sharp. After acute kidney injury, a substantial subset of patients do not recover cleanly; instead, they slide into chronic kidney disease with persistent structural damage and scarring. Baseline epidemiology and translational data have struggled to explain why some kidneys repair and others lock into fibrosis. In this work, elevated circulating lactate stood out as an independent predictor of chronic kidney disease development in patients with acute kidney injury in the UK Biobank cohort, and it tracked with fibrotic progression rather than serving as a passive metabolic footnote.

The biologic logic is plausible at the bedside. Injured kidneys live in a low-oxygen, high-stress environment where metabolic rewiring is common, but the idea that lactate can modify protein behavior and redirect RNA biology gives the injury-to-fibrosis shift a much more active molecular engine.

DDX18 lactylation redirects a nucleolar helicase into the nucleoplasm

The central molecular finding is a posttranslational modification on the RNA helicase DDX18. In murine ischemia-reperfusion models, lactate promoted p300-mediated lactylation at lysine 116, and this change disrupted DDX18’s nucleolar retention. Instead of remaining confined to the nucleolus, the protein redistributed into the nucleoplasm, where it gained stronger affinity for CD44 mRNA.

One sentence captures the shift: the protein moved compartments, and the transcript became harder to clear.

That relocalization mattered because RNA stability is not a passive property. When DDX18 bound CD44 mRNA more effectively, the transcript persisted longer, which amplified fibrotic signaling pathways. The study places RNA helicase biology squarely inside the fibrosis program, showing that a change in subcellular positioning can alter messenger RNA fate and, in turn, push injured tissue toward chronic scarring.

This mechanism also explains why lactate should not be dismissed as a late marker of injury. Here it acts upstream, shaping protein chemistry, intracellular trafficking, and transcript stability in one connected pathway.

Fibrotic signaling intensifies as renal structure and function deteriorate

The murine data tied the molecular findings to organ-level injury. In ischemia-reperfusion models, lactate-driven DDX18 lactylation coincided with sustained renal damage and fibrosis. When investigators disrupted the pathway, renal injury lessened, structural staining improved, and fibrotic markers fell across molecular and histologic readouts.

Figure-level data reinforce the same pattern in tubular epithelial cells. TEC-specific DDX18 ablation in BIRI mice led to better renal function, with lower serum creatinine, uric acid, and BUN on day 14. Histology followed the biochemical changes: H&E, PAS, and Sirius Red staining all showed less injury and less collagen deposition in the knockout animals. At the transcript and protein level, fibrotic markers dropped, and the histologic signal was reduced as well.

The in vitro arm extended the argument. DDX18-deficient HK-2 cells exposed to hypoxia/reoxygenation migrated less efficiently in scratch wound assays, and wound closure at 48 hours was impaired compared with DDX18-sufficient cells. Fibrotic marker expression also fell by RT-qPCR, Western blotting, and immunofluorescence. In practical terms, DDX18 appears to help injured tubular cells adopt a pro-fibrotic, motile phenotype that favors maladaptive repair.

A kidney-targeted peptide interrupts the lactylation switch

Therapeutic relevance usually hinges on whether a pathway can be blocked without wrecking normal physiology. Here, the investigators developed a kidney-targeted, cell-penetrating peptide designed to inhibit DDX18 K116 lactylation. In the injury models, the peptide attenuated fibrotic progression in the kidney.

That is an important proof-of-concept because it moves the biology from association to intervention. A targeted inhibitor aimed at a discrete posttranslational event offers a cleaner strategy than blanket suppression of lactate production, which could disrupt normal metabolism in many tissues. The peptide approach also reflects the anatomic reality of kidney injury: the cortex and tubules are exposed to broad metabolic stress, yet treatment still needs to act with enough specificity to avoid collateral damage.

For nephrology, the promise lies in the pathway architecture. Lactate rises in injured tissue, p300 installs the modification, DDX18 exits the nucleolus, CD44 mRNA becomes more stable, and fibrosis accelerates. Each step gives the process a measurable handle for drug development.

Why the AKI-to-CKD transition now looks more targetable

This study reframes post-injury fibrosis as a disorder of RNA handling as much as one of inflammation or extracellular matrix deposition. CD44 has long been tied to tissue remodeling and fibro-inflammatory signaling, and its increased stability fits the profile of a kidney that has stopped repairing normally. By linking metabolic stress to RNA helicase trafficking, the work adds a distinct mechanistic layer to chronic kidney disease progression.

The human cohort signal strengthens the translational case, but the findings still need careful clinical validation before any therapeutic leap. The UK Biobank association identifies risk, not causality, and the peptide strategy has been tested in experimental systems rather than in patients. Even so, the data provide a coherent roadmap: lactate is not only a biomarker of injured kidney metabolism, it is part of the machinery that helps convert acute damage into chronic fibrosis.

For now, the most concrete implication is biological rather than procedural. If DDX18 lactylation can be blocked early after kidney injury, the fibrotic cascade may be harder to sustain. The unanswered issues are clinical timing, durability of effect, and whether this pathway can be safely modulated in human acute kidney injury without disrupting the broader metabolic response that injured tissue still requires.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Journal of Clinical Investigation.